Navigation Links
ForteBio Introduces BLItz™, a Revolutionary, Micro-volume Label-free Analysis Platform for Personal Assays
Date:12/5/2011

SAN DIEGO, Dec. 5, 2011 /PRNewswire/ -- ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of BLItz™, a revolutionary new platform that will enable scientists – for the first time – to conduct label-free analyses of proteins using small sample volumes easily and cost-efficiently at their lab bench. The new platform was unveiled today at the IBC Antibody Engineering and Therapeutics Conference in San Diego, Calif. (Booth #206 at the Hilton San Diego Bayfront Hotel).

"With BLItz, researchers will be able to perform specific protein quantitation, kinetics and affinity analyses of protein interactions with just a drop of sample in a simple 'drop, read, done' format at a price point below $20,000 per instrument," said Christopher Silva, ForteBio's vice president of marketing. "We believe BLItz will revolutionize the use of label-free protein analysis by making it more accessible than ever to individual bench scientists throughout the world. Ultimately, this will help to further drive basic research and biotherapeutic development."

Historically, label-free assays have been used selectively and relegated to institutions' core labs due to their high complexity and expense. This has traditionally produced bottlenecks in biotherapeutic research and development as scientists may wait days and weeks to schedule their experiments and then hours or longer to obtain results. BLItz is small – taking up less surface area than a tablet personal computer – so it can fit easily in an individual scientist's workspace and is simple to use. It requires only four microliters of sample – which is 15 to 20 times less volume than needed for traditional, SPR-based label-free assays or microplate-based ELISA assays. Additionally, its Dip and Read™ assays utilize disposable, ready-to-use biosensors to uniquely provide results in seconds to minutes.

BLItz utilizes the same BioLayer Interferometry (BLI) technology that powers ForteBio's flagship Octet® instrumentation platform, which enables real-time kinetics, affinity and quantitation measurements in high-throughput applications, with unprecedented ease of use and cost-efficiency.

"ForteBio has a history of delivering disruptive technologies that have re-invented the label-free protein analysis space," said Joseph D. Keegan, Ph.D., ForteBio's chief executive officer. "In just seven years, many leading academic, government and corporate institutions have adopted our Octet platform and have consumed more than four million biosensors for use on the system. We look forward to making similar inroads with our new BLItz platform and anticipate that BLItz will help fuel further growth in proteomics."

The new BLItz system is designed for any researcher working with proteins, particularly those who analyze column fractions, monitor protein expression, perform reagent QC, identify mechanism of action and signaling and run protein engineering studies.  More information about BLItz can be found at www.BlitzMeNow.com.

ABOUT FORTEBIO, INC.

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.


'/>"/>
SOURCE ForteBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ForteBio Launches Dip and Read™ Anti-GST Biosensor
2. ForteBio Introduces New Biosensor for Kinetic Analysis and Screening of Mouse IgG Antibodies
3. ForteBio Launches New Octet® RED96 System and Dip and Read™ Protein L Biosensor
4. ForteBio Announces Launch of Protein G Biosensor for Use on Companys Octet® Instruments
5. ForteBio Launches New Dip and Read(TM) Residual Protein A Detection Kit; Introduces Sidekick(TM) Offline Biosensor Immobilization Station for All Octet(R) Instruments
6. Weld County Introduces Prescription Discount Card to Help Alleviate High Costs
7. Boston Scientific Introduces Industry-Leading ICD and CRT-D Device Warranties
8. Instrumentation Laboratory Introduces Automated HemosIL VWF Ristocetin Cofactor Activity Assay in Europe and International Regions
9. Hamamatsu Introduces the ORCA-Flash4.0 Scientific CMOS Camera With High Sensitivity, High Resolution, and Fast Readout
10. Omnicell Introduces Groundbreaking Mandarin-Language Medication Automation System for Use in Chinese Clinical Settings
11. Hologic Introduces Synthesized 2D Image Algorithm Designed to Eliminate the Need for a 2D Mammogram in a 2D plus 3D Tomosynthesis Exam
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... and BLOOMINGTON, Minn. , ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical ... ("Precision Lens"), today announced the signing of a ... Precision Lens will deploy a dedicated sales team ... in the U.S., primarily focused in 13 states ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, ... its strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a ... effective management of complex spine deformity cases, particularly in children. , GSO’s focus ...
(Date:4/24/2017)... Lake City, UT (PRWEB) , ... April 24, 2017 , ... ... their efforts to encourage sustainability, innovate new strategies to reduce waste, and support renewable ... herbal remedy provider. They look to nature to find solutions for health issues, and ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The California Dental ... in charitable dental services to 1,961 people during the April 22-23 event at the ... charge to Californians who experience barriers to care, CDA Cares educates the public and ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... seeking public support to bring their novel lifesaving device for the everyday use ... with medical-grade sensors, specially designed to read a child’s vital signs, and detect ...
(Date:4/24/2017)... CA (PRWEB) , ... April 24, 2017 , ... ... brain tumors are expected to be diagnosed globally; approximately 25,000 of them will ... are anticipating greater use of this type of healthcare model in the diagnosis ...
Breaking Medicine News(10 mins):